These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31145139)

  • 1. All-Cause Mortality and Cardiovascular Outcomes With Non-Vitamin K Oral Anticoagulants Versus Warfarin in Patients With Heart Failure in the Food and Drug Administration Adverse Event Reporting System.
    von Lueder TG; Atar D; Agewall S; Jensen JK; Hopper I; Kotecha D; Mentz RJ; Kim MH; Serebruany VL
    Am J Ther; 2019; 26(6):e671-e678. PubMed ID: 31145139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and Safety of Contemporary Oral Anticoagulants Among Asians With Nonvalvular Atrial Fibrillation.
    Lee SR; Choi EK; Kwon S; Han KD; Jung JH; Cha MJ; Oh S; Lip GYH
    Stroke; 2019 Aug; 50(8):2245-2249. PubMed ID: 31208303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
    Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y
    Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mortality and oral anticoagulants in the Food and Drug Administration Adverse Event Reporting System.
    Serebruany V; Cherepanov V; Fortmann S; Kim MH
    Open Heart; 2017; 4(2):e000629. PubMed ID: 28761683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
    Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons.
    Verdecchia P; Angeli F; Lip GY; Reboldi G
    PLoS One; 2014; 9(6):e100478. PubMed ID: 24955573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-vitamin K antagonist oral anticoagulants and heart failure.
    Isnard R; Bauer F; Cohen-Solal A; Damy T; Donal E; Galinier M; Hagège A; Jourdain P; Leclercq C; Sabatier R; Trochu JN; Cohen A
    Arch Cardiovasc Dis; 2016 Nov; 109(11):641-650. PubMed ID: 27836786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study.
    Durand M; Schnitzer ME; Pang M; Carney G; Eltonsy S; Filion KB; Fisher A; Jun M; Kuo IF; Renoux C; Paterson JM; Quail J; Matteau A;
    CMAJ Open; 2020; 8(4):E877-E886. PubMed ID: 33355273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation.
    Wu S; Xie S; Xu Y; Que D; Yau TO; Wang L; Huang Y
    J Clin Nurs; 2019 May; 28(9-10):1839-1846. PubMed ID: 30667111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Intracerebral Hemorrhage Among Patients Taking Non-Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality.
    Inohara T; Xian Y; Liang L; Matsouaka RA; Saver JL; Smith EE; Schwamm LH; Reeves MJ; Hernandez AF; Bhatt DL; Peterson ED; Fonarow GC
    JAMA; 2018 Feb; 319(5):463-473. PubMed ID: 29372247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.
    Briere JB; Bowrin K; Millier A; Toumi M; Wojciechowski P; Taieb V
    J Med Econ; 2019 Aug; 22(8):760-765. PubMed ID: 30969801
    [No Abstract]   [Full Text] [Related]  

  • 14. Risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy.
    Lee HJ; Kim HK; Kim BS; Han KD; Park JB; Lee H; Lee SP; Kim YJ
    PLoS One; 2021; 16(6):e0253310. PubMed ID: 34138972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation.
    Brown JD; Shewale AR; Talbert JC
    J Manag Care Spec Pharm; 2016 Nov; 22(11):1319-1329. PubMed ID: 27783556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness Analysis of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Thai Patients With Non-Valvular Atrial Fibrillation.
    Dilokthornsakul P; Nathisuwan S; Krittayaphong R; Chutinet A; Permsuwan U
    Heart Lung Circ; 2020 Mar; 29(3):390-400. PubMed ID: 31000364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke.
    Kanai Y; Oguro H; Tahara N; Matsuda H; Takayoshi H; Mitaki S; Onoda K; Yamaguchi S
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):338-345. PubMed ID: 29033229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of heart failure in elderly patients with atrial fibrillation and diabetes taking different oral anticoagulants: a nationwide cohort study.
    Lin SM; Liu PP; Tu YK; Lai EC; Yeh JI; Hsu JY; Munir KM; Peng CC; Huang HK; Loh CH
    Cardiovasc Diabetol; 2023 Jan; 22(1):1. PubMed ID: 36609317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
    Skjøth F; Larsen TB; Rasmussen LH; Lip GY
    Thromb Haemost; 2014 May; 111(5):981-8. PubMed ID: 24577485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why switch from warfarin to NOACs?
    Verdecchia P; Angeli F; Aita A; Bartolini C; Reboldi G
    Intern Emerg Med; 2016 Apr; 11(3):289-93. PubMed ID: 26972708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.